April 15, 2021 09:51 AM EDT
FDA+

PDU­FA VII to ex­pand FDA’s re­al-time on­col­o­gy re­views to sup­ple­ments for all ther­a­peu­tic ar­eas

Zachary Brennan

Senior Editor

The FDA’s pop­u­lar pro­gram to speed up its re­views of new on­col­o­gy drugs and sup­ple­men­tal ap­pli­ca­tions by months will be ex­pand­ed in­to a larg­er pro­gram …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times